M. Venturi

发表

Y. Gerchman, E. Padan, M. Venturi, 2001, Biochimica et biophysica acta.

Predictive markers in early research and companion diagnostic developments in oncology.

M. Venturi, M. Pickl, E. Ruge, 2012, New biotechnology.

Tyrosine Sulfation of Human Antibodies Contributes to Recognition of the CCR5 Binding Region of HIV-1 gp120

Christoph Grundner, Peter D. Kwong, Wenhui Li, 2003, Cell.

Quantification of HER 2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded ( FFPE ) Breast Cancer Tissues *

P. Lescuyer, D. Hochstrasser, P. Cutler, 2015 .

Structure of the Na + /H + antiporter NhaA

E. Padan, M. Venturi, H. Michel, 2006 .

Serum Trypsinogen Activation Peptide in the Assessment of the Diagnosis and Severity of Acute Pancreatic Damage: A Pilot Study Using a New Determination Technique

M. Venturi, R. Pezzilli, A. Morselli-Labate, 2004, Pancreas.

Monoclonal antibodies for the structural analysis of the Na+/H+ antiporter NhaA from Escherichia coli.

M. Venturi, C. Hunte, 2003, Biochimica et biophysica acta.

The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120

Peter D. Kwong, Hermann Katinger, H. Katinger, 2002, Journal of Virology.

Structure of a Na+/H+ antiporter and insights into mechanism of action and regulation by pH

Hartmut Michel, Carola Hunte, E. Padan, 2005, Nature.

Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1

Christoph Grundner, Christos J. Petropoulos, Terri Wrin, 2003, Journal of Virology.

Oligomerization of NhaA, the Na+/H+ antiporter of Escherichia coli in the membrane and its functional and structural consequences.

Y. Gerchman, E. Padan, M. Venturi, 2001, Biochemistry.

The Monoclonal Antibody 1F6 Identifies a pH-dependent Conformational Change in the Hydrophilic NH2 Terminus of NhaA Na+/H+ Antiporter ofEscherichia coli *

Y. Gerchman, E. Padan, M. Venturi, 2000, The Journal of Biological Chemistry.

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

J. Larkin, M. Venturi, J. Schellens, 2014, Clinical Cancer Research.

Expression of Serine/Threonine Protein-Kinases and Related Factors in Normal Monkey and Human Retinas: The Mechanistic Understanding of a CDK2 Inhibitor Induced Retinal Toxicity

Michael Pawlak, M. Venturi, A. Giusti, 2007, Toxicologic pathology.

Access of antibody molecules to th conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary HIV-1

J. Sodroski, J. Binley, R. Wyatt, 2009 .

CD4 Binding Site Antibodies Inhibit Human Immunodeficiency Virus gp120 Envelope Glycoprotein Interaction with CCR5

J. Sodroski, M. Venturi, P. Kwong, 2003, Journal of Virology.

Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches

Li Lu, Michael Pawlak, Jean Tessier, 2014, EJNMMI Research.

Quantification of HER2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues*

P. Lescuyer, D. Hochstrasser, P. Cutler, 2015, Molecular & Cellular Proteomics.

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

Peter D. Kwong, Wayne A. Hendrickson, Michael L. Doyle, 2002, Nature.

Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120.

Wayne A Hendrickson, Peter D Kwong, Joseph Sodroski, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Multiple Protein Analysis of Formalin-fixed and Paraffin-embedded Tissue Samples with Reverse phase Protein Arrays

Michael Pawlak, Hanno Langen, Markus F. Templin, 2013, Molecular & Cellular Proteomics.

Kinetics of charge translocation in the passive downhill uptake mode of the Na+/H+ antiporter NhaA of Escherichia coli.

E. Bamberg, E. Padan, M. Venturi, 2005, Biochimica et biophysica acta.

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

M. Venturi, D. Skene, P. Workman, 2017, Molecular Cancer Therapeutics.

Production and characterization of monoclonal antibodies directed against native epitopes of NhaA, the Na+/H+ antiporter of Escherichia coli

E. Padan, M. Venturi, H. Michel, 1998, FEBS letters.

Paraffin-Embedded Breast Cancer Tissues

F. Roche, P. Lescuyer, D. Hochstrasser, 2015 .

A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity

C. Klein, M. Venturi, M. Majety, 2013, Oncogene.

High level production of functional antibody Fab fragments in an oxidizing bacterial cytoplasm.

M. Venturi, C. Hunte, C. Seifert, 2002, Journal of molecular biology.

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

J. Larkin, M. Venturi, J. Schellens, 2014, Clinical Cancer Research.

Assessing and managing toxicities induced by kinase inhibitors.

Giulia Pennella, Pietro Grossi, M. Venturi, 2007, Current opinion in drug discovery & development.